Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
Provided By GlobeNewswire
Last update: May 7, 2025
– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 –
– Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer’s disease in Q3 2025 –
Read more at globenewswire.com7.89
+0.01 (+0.13%)
Find more stocks in the Stock Screener
VIGL Latest News and Analysis
5 days ago - ChartmillOn Tuesday, there are stocks with unusual volume. Let's take a look.Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
9 days ago - ChartmillWhich stocks have an unusual volume on Friday?In today's session, these stocks are experiencing unusual volume.
